CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry

Abroad (travel likely)Recruiting

Conditions

Atopic Dermatitis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

CorEvitas, LLC, Waltham, Massachusetts, United States
Contact: Study coordinator (Cathy Cheney) · corevitasregistrytrials@corevitas.com · 508-555-1212

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE3

Birmingham, United States · Bryant, United States

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Moderate-to-Severe Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE3

St. Petersburg, United States

HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis

Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE1, PHASE2

Hangzhou, China

A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)

Atopic Dermatitis (AD)

Abroad (travel likely)Recruiting

Beijing, China